[Skip to Content]
[Skip to Content Landing]
Commentary
September 17, 2008

Sequential Therapy for Helicobacter pylori: Time to Consider Making the Switch?

Author Affiliations

Author Affiliations: University of Wisconsin School of Medicine and Public Health, Madison (Dr Vakil); and University of Bologna, Bologna, Italy (Dr Vaira).

JAMA. 2008;300(11):1346-1347. doi:10.1001/jama.300.11.1346

Helicobacter pylori infection remains an important cause of morbidity and mortality worldwide. Attempts at developing a vaccine have failed, and the current focus for clinicians is the treatment of the infection. Eradication of H pylori has been shown to prevent recurrent peptic ulcer disease, to cure some localized gastric mucosa–associated lymphoid tissue lymphomas, and to prevent nonsteroidal anti-inflammatory drug (NSAID)–related ulcers in patients who are initiating long-term NSAID therapy.1 In recent years, the rate of treatment failure associated with established drug regimens has increased at a rapid rate.2

×